FGF-2 Polyclonal Antibody
¥680.00
CTIP (Phospho Ser327) rabbit pAb
活动价：
¥680.00
市场价：¥880.00
一键复制产品信息
产品规格：
- 50μL
- 100μL
货号：
FAB2612299
- 产品信息
商品描述
靶点-Target
CTIP
反应性
Human,Mouse
应用
WB,ELISA
宿主物种-Host Species
Rabbit
同种型-Isotype
IgG
修饰-Modification
Phospho
MW(Observed)
100kD
推荐稀释比
WB 1:1000-2000;ELISA 1:5000-20000
组成
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
纯化工艺
The antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen.
储存
-15°C to -25°C/1 year(Do not lower than -25°C)
浓度
1 mg/ml
克隆性
Polyclonal
免疫原
Synthesized peptide derived from human CTIP (Phospho Ser327)
特异性
This antibody detects endogenous levels of Human,Mouse CTIP (Phospho Ser327)
基因名称
RBBP8 CTIP
蛋白名称
CTIP (Phospho Ser327)
别名
DNA endonuclease RBBP8;CtBP-interacting protein;CtIP;Retinoblastoma-binding protein 8;RBBP-8;Retinoblastoma-interacting protein and myosin-like;RIM;Sporulation in the absence of SPO11 protein 2 homolog;SAE2;
Organism-1
Human
基因ID-1
5932
SwissProt-1
Q99708
Organism-2
Mouse
基因ID-2
225182
SwissProt-2
Q80YR6
Organism-3
Rat
基因ID-3
291787
SwissProt-3
B1WC58
背景
The protein encoded by this gene is a ubiquitously expressed nuclear protein. It is found among several proteins that bind directly to retinoblastoma protein, which regulates cell proliferation. This protein complexes with transcriptional co-repressor CTBP. It is also associated with BRCA1 and is thought to modulate the functions of BRCA1 in transcriptional regulation, DNA repair, and/or cell cycle checkpoint control. It is suggested that this gene may itself be a tumor suppressor acting in the same pathway as BRCA1. Three transcript variants encoding two different isoforms have been found for this gene. More transcript variants exist, but their full-length natures have not been determined. [provided by RefSeq, Jul 2008],
细胞定位
Nucleus . Chromosome . Associates with sites of DNA damage in S/G2 phase (PubMed:10764811, PubMed:25349192). Ubiquitinated RBBP8 binds to chromatin following DNA damage (PubMed:16818604). .
